NKTR - Nektar Therapeutics GAAP EPS of -$0.27 beats by $0.01 revenue of $20.5M misses by $1.33M
2023-08-08 17:00:29 ET
- Nektar Therapeutics press release ( NASDAQ: NKTR ): Q2 GAAP EPS of -$0.27 beats by $0.01 .
- Revenue of $20.5M (-5.1% Y/Y) misses by $1.33M .
- Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to $505.0 million at December 31, 2022. Nektar's cash and marketable securities are expected to support strategic development activities and operations into at least the middle of 2026.
For further details see:
Nektar Therapeutics GAAP EPS of -$0.27 beats by $0.01, revenue of $20.5M misses by $1.33M